BCMA CAR mRNA (m1Ψ, Cap1)
The BCMA CAR mRNA encodes a chimeric antigen receptor (CAR) designed to specifically target B-cell maturation antigen (BCMA), a cell surface marker highly expressed on malignant plasma cells in multiple myeloma. Upon transfection, this mRNA enables transient CAR expression in immune effector cells such as T cells or NK cells, empowering them to recognize and eliminate BCMA⁺ tumor cells efficiently.
The CAR construct includes an anti‑BCMA scFv, hinge and transmembrane regions, and intracellular signaling domains—typically 4‑1BB and CD3ζ—that support potent activation and sustained cytotoxic activity. Delivered as a high-quality, non‑integrating reagent, the BCMA CAR mRNA offers an effective approach for CAR engineering, functional studies, and preclinical development of multiple myeloma therapies.
Product Features
Cap1 structure with high capping efficiency for enhanced translation.
Codon optimization using GenScript X5 algorithm for improved expression.
100% substitution with N¹‑methyl‑pseudouridine (m1Ψ) for higher stability and reduced innate immune response.
100A poly(A) tail that mirrors mature eukaryotic mRNA.
Enables transient, non‑viral CAR expression—ideal for research and validation experiments.
Product Specifications
Form: Liquid
Concentration: 1 mg/mL
Full mRNA Length: 1738 nt
Molecular Weight: 560,055 Da
Buffer: 1 mM Sodium citrate, pH 6.5
Storage: Store at –20 °C for short term (<3 months) or –80 °C for long term.
Shipping Method: Dry ice
Quality Control
Appearance: Clear and free of foreign particles
RNA Length: Expected size band detected
RNA Content: Target ± 5%
Integrity: ≥ 75%
OD260/OD280: 1.70–2.30
Capping Efficiency: ≥ 90%
Endotoxin: < 10 EU/mg
pH: Target ± 0.5
For research use only.
Contact us for bulk orders, custom mRNA designs, or additional modifications.
BCMA CAR mRNA (m1Ψ, Cap1)
ℹ️ More Information
🛠️ Custom LNP Service
⚗️ LNP Formulation Equipment
){kind=link}